Business
NKGen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose-Responsive Cognitive Improvements and Biomarker Correlations in Alzheimer’s Disease at AD/PD 2026™
Pooled analyses in patients with moderate Alzheimer’s show dose-related cognitive benefit and signs of durability. 100% of patients remained stable or improved, with 50% improving from moderate to mild cognitive function. Exploratory plasma GFAP correlations are consistent with observed clinical outcomes. Findings support further evaluation of troculeucel’s immunomodulatory approach in the ongoing Phase 2 trial. SANTA ANA, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN
About this update from Nkgen Biotech Inc.
[{"type":"image","alt":"NKGen Biotech, Inc.","displaySize":"","headline":null,"caption":"NKGen Biotech, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":88,"url":"https://media.zenfs.com/en/globenewswire.com/6148ed3e2e28e6c539be48d0406ad510"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Ui_febjO_II.F5hi8oLzdw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMw--/https://media.zenfs.com/en/globenewswire.com/6148ed3e2e28e6c539be48d0406ad510","width":300,"height":88}},"lazy":false},{"type":"text","content":"Pooled analyses in patients with moderate Alzheimer’s show dose-related cognitive benefit and signs of durability.","length":114,"tagName":"p"},{"type":"text","content":"100% of patients remained stable or improved, with 50% improving from moderate to mild cognitive function.","length":106,"tagName":"p"},{"type":"text","content":"Exploratory plasma GFAP correlations are consistent with observed clinical outcomes.","length":84,"tagName":"p"},{"type":"text","content":"Findings support further evaluation of troculeucel’s immunomodulatory approach in the ongoing Phase 2 trial.","length":108,"tagName":"p"},{"type":"text","content":"SANTA ANA, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced new data presented at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (“AD/PD™ 2026”), held March 17-21, 2026, in Copenhagen, Denmark and virtually.","length":503,"tagName":"p"},{"type":"text","content":"NKGen’s combined Phase 1 analyses from two previously completed open-label Phase 1 trials of troculeucel in Alzheimer’s disease (AD) demonstrated encouraging signs of biological activity, with 92% of patients having stable and/or improved cognitive function. Subsequent additional analyses focusing solely on the moderate stage population demonstrated clear dose‑responsive cognitive trends with no observed decline across all treated patients. Higher doses were associated with more frequent clinically meaningful improvements and early indications of durability were seen at the final 12-month assessment in patients. Importantly, exploratory plasma Glia...